Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Fear Extinction in PTSD
NCT06788522Phase 4Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2026
- Primary completion
- Mar 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-traumatic stress disorder (PTSD) and Insomnia comparing Suvorexant with Placebo (2 arms). Primary endpoints: Enrollment, Medication Adherence and 5 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
suvorexant
03
Conditions
post-traumatic stress disorder (PTSD)Insomnia
Beyond the preview
Go deeper on NCT06788522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788522.